

2020 Conference Market Analysis

Journal of Biomedical and Pharmaceutical Sciences

Nelly Adel, J Biomed Pharm Sci 2019, 2:3

### **Conference Market Analysis: Biosimilars-2020**


### Nelly Adel

Pharmacy Practice Touro College of Pharmacy USA, E-mail: nelly.adel@touro.edu

After the successful completion of the <u>Biosimilars 2019</u> conference series, we are pleased to welcome you to the "International Conference on Biosimilars-Biologics and Biomarkers." The congress is scheduled to take place on November 16-17, 2020 in the beautiful city of London, UK. This Biosimilars-2020 <u>Conference</u> will give you exemplary experience and great insights in the field of research.

Biosimilars-2020 conveys recent developments in Pharma drug marketing and production of Pharma drugs and contract manufacturing. A complete knowledge of a scientific discipline that described the effects of Biosimilars drug marketing and Biosimilars Pharma now explores the Scope of Biosimilars drug marketing in industry & provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs.

As per market researchers the global "<u>Biosimilars</u> Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023", The <u>biosimilars</u> market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%. Granulocyte colony-stimulating factors (G-CSFs) reached \$379.3 million in 2013. This segment is expected to increase from \$453.6 million in 2014 to \$1.1 billion by 2019, a CAGR of 20.2% from 2014 to 2019.



Source: BCC Research

### Importance & Scope:

The European-based <u>pharmaceutical industry</u> makes a major contribution to the Europe, not just in financial terms but also in terms of high-trait employment. Globally Pharma Market ranges from \$870-\$900 billion and in Europe \$260-\$280 billion.

### A global biosimilars strategy:

Developed markets: Developed markets, with the exception of the United States, represent the greatest today. biosimilars presence Most biosimilars manufacturers have been and remain focused on the developed markets - whether it is for their historic and current opportunities (EU) or for their future market potential (United States, Japan). Dedicated regulatory pathways set the foundation for stringent, abbreviated approval processes which, in turn, have fed investor enthusiasm. **Biosimilars** adoption in developed markets has been primarily payer-driven, especially in European markets, given payers' urgent, unmet need to contain public health care expenditures. Further market uptake has been slowed by prescribers' skepticism and low patient awareness. Still, developed markets continue to have the highest number of biosimilars molecules in development - estimated at 29 in Europe, 19 in the United States and seven in Japan.

Emerging markets: In today's emerging markets, biosimilars are still nascent, with little to no presence. However, in contrasting emerging markets with developed markets, the limited patient access to affordable <u>biologics</u> and the openness of physicians to low-cost therapies may offer potentially significant opportunities. Today, emerging markets represent a snippet of total world <u>biologic</u> sales in value, less than seven to eight percent (versus 48.6 percent in the United States).ix Treatment rates for flagship biologics are still low compared to developed markets, despite existing demand. For example, the treatment rate of Mab Thera® in Brazil is three times lower than in the UK and six times lower than in the US.x Additionally, a recent Kantor Health Survey found that 20 percent of emerging market autoimmune patients use a <u>biologic</u>, with the distribution of biologics varying from 29 percent in China to 12 percent in Russia and a mere 6 percent in Brazil.xi This may indicate the presence of large pockets of non-consumption, especially within the growing middle class.

Biosimilars Market Projected To Reach \$41.7 Billion By 2024. Biosimilars Market, by Product (Revenue, USD Million, 2017 - 2024)

- Recombinant Non-Glycosylated Proteins
- Insulin
- Human Growth Hormones
- Granulocyte Colony-stimulating Factor (G-CSF)
- > Interferons
- Recombinant Glycosylated Proteins
- > Erythropoietin
- Monoclonal Antibodies
- ➢ Follitropin

## Biosimilars Market, by Application (Revenue, USD Million, 2017 - 2024)

- Oncology
- Blood Disorders
- Growth Hormone Deficiency
- Chronic and Autoimmune Disorders
- Others


# Biosimilars Market, by Region (Revenue, USD Million, 2017 - 2024)

- North America
  - U.S.
  - o Canada
- Europe
  - o UK
    - o Germany
- Asia Pacific
  - o China
  - o India

- Rest of the World
  - o Brazil
  - o Russia

### **Critical Analysis:**

The capital-intensive nature of the <u>bio similar</u> business and long gestation periods between initial investment and commercialization require bio similar players to take a higher level of risk than their counterparts in the small molecule generics business, and this can be a significant barrier to entry for many start-ups.



### Major Biosimilars Associations in Europe

- Pro Generika
- German Association of Generic Manufacturers
- German Association of Research-Based Pharmaceutical Companies
- German Association for the Pharmaceutical Industry
- Generics and Biosimilars Initiative
- The Biosimilars Resource Center
- The Alliance for Safe Biologic Medicines

#### Contact Person: Girisha TL | Program Manager

Email: <u>biosimilars@theannualmeet.com</u> Contact No: +442036082897 Whatsapp: +44-1785-508016